GenSight Biologics S.A.
SIGHT | PA
Overview
Corporate Details
- ISIN(s):
- FR0013183985 (+3 more)
- LEI:
- 549300NK4AB8OUEX1F54
- Country:
- France
- Address:
- 74 RUE DU FAUBOURG SAINT-ANTOINE, 75012 PARIS
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-26 07:30 |
Regulatory News Service
Inside Information / Other news releases
|
English | 165.8 KB | |
| 2025-06-26 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 155.9 KB | |
| 2025-06-12 19:02 |
Regulatory News Service
Inside Information / Other news releases
|
English | 207.0 KB | |
| 2025-06-12 19:02 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 176.7 KB | |
| 2025-05-13 22:00 |
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
|
English | 85.1 KB | |
| 2025-05-13 22:00 |
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
|
French | 114.2 KB | |
| 2025-04-23 20:30 |
General Meeting Notice
Inside Information / Other news releases
|
English | 82.1 KB | |
| 2025-04-23 20:30 |
General Meeting Notice
Informations privilégiées / Autres communiqués
|
French | 113.3 KB | |
| 2025-04-08 15:55 |
Annual Report (ESEF)
URD 2024
|
English | 22.4 MB | |
| 2025-04-08 07:00 |
Regulatory News Service
INSIDE INFORMATION / OTHER NEWS RELEASES
|
English | 88.3 KB | |
| 2025-04-08 07:00 |
Regulatory News Service
INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS
|
French | 116.7 KB | |
| 2025-04-07 20:30 |
Regulatory News Service
URD 2024
|
French | 47.7 KB | |
| 2025-04-07 20:14 |
Capital/Financing Update
Inside Information / News release on accounts, results
|
English | 154.8 KB | |
| 2025-04-07 20:14 |
Capital/Financing Update
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 176.5 KB | |
| 2025-03-19 18:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 328.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-09 | N/A | Other | Other | 5,063,291 | 1,999,999.95 EUR |
| 2024-02-07 | N/A | Other | Other | 5,224,660 | 1,999,999.85 EUR |
| 2023-11-21 | N/A | Other | Other | 3,038,279 | 2,163,862.30 EUR |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |